Editorial Meandering Pathway Leading From Genotyping to Personalized Management of Long-QT Syndrome

Long-QT syndrome (LQTS) has been the first inheritedarrhythmogenic syndrome to be extensively character-ized in clinical cardiology. Its genetic bases were disclosed in the early 1990s by Keating’s group, opening the field of molecular arrhythmology.1–3 The publication of Keating’s works generated a great deal of excitement among those involved in the care of LQTS patients because it became clear that the possibility of identifying in the clinic the DNA variants that cause LQTS would affect the clinical manage-ment of families affected by the disease. Article see p 1988 A major breakthrough in the application of clinical genet-ics to clinical practice came shortly after the discovery of the genes for the 3 most prevalent variants of the disease (ie, LQT1, LQT2, and LQT3) when Moss and colleagues4 showed that the morphology of the ST-T–wave comple